Dova Pharmaceuticals (NASDAQ:DOVA) announces the commercial availability of DOPTELET (avatrombopag) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia who have failed to adequately respond to previous therapy.
The FDA approved the expanded use last month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.